

Ashley B Grossman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7744107/ashley-b-grossman-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224
papers

11,347
citations

54
h-index

101
g-index

235
ext. papers

13,274
ext. citations

5.9
avg, IF

6.44
L-index

#	Paper	IF	Citations
224	"The past is a different country, they do things differently there": using the SEER data-base to assess prognosis in neuroendocrine tumours.. <i>Endocrine</i> , 2022 , 75, 725	4	0
223	A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15 U/kg vs. 0.10 U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 Cases.. <i>International Journal of Endocrinology</i> , 2022 , 2022, 7360282	2.7	
222	Cushing's Syndrome 2022 , 79-90		
221	The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e13052	3.8	1
220	Thought for food: a Cushing's syndrome enigma explained. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 800-801	18.1	
219	Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients. <i>Neuroendocrinology</i> , 2021 , 111, 863-875	5.6	2
218	Diabetes insipidus secondary to sellar/parasellar lesions. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e129548	3.8	2
217	Misleading GALLIUM-dotatate PET scan in a patient with a history of a pheochromocytoma: Unsuspected uptake in papillary thyroid carcinoma metastases. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e12964	3.8	1
216	Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. <i>European Journal of Endocrinology</i> , 2021 , 184, P1-P16	6.5	6
215	Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 179-204	10.5	6
214	Treating neuroendocrine neoplasms in the setting of HIV infection. <i>Translational Science of Rare Diseases</i> , 2021 , 5, 143-159	3.3	0
213	Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. <i>Endocrine Connections</i> , 2021 , 10, 387-400	3.5	1
212	Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review and narrative synthesis. <i>Endocrine Connections</i> , 2021 , 10, 447-461	3.5	0
211	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. <i>Modern Pathology</i> , 2021 , 34, 1634-1650	9.8	7
210	COVID-19-related thyroiditis: A novel disease entity?. <i>Clinical Endocrinology</i> , 2021 , 95, 369-377	3.4	14
209	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 435-444	15.2	12
208	Changing biological behaviour of NETs during the evolution of the disease: progress on progression. <i>Endocrine-Related Cancer</i> , 2021 , 28, R121-R140	5.7	6

207	A clinical approach to parasellar lesions in the transition age. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e12995	3.8	1
206	Personalized management of pheochromocytoma and paraganglioma. <i>Endocrine Reviews</i> , 2021 ,	27.2	18
205	Can COVID-19 immunisation cause subacute thyroiditis?. <i>Clinical Endocrinology</i> , 2021 ,	3.4	10
204	Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease. <i>Endocrine</i> , 2021 , 72, 279-286	4	4
203	The diagnosis of Cushing's disease 2021 , 219-229		
202	Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2021 , 32, 169-191	4.2	10
201	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvaa205	0.4	14
200	Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency. <i>Frontiers in Endocrinology</i> , 2021 , 12, 641247	5.7	0
199	Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4903-e4916	5.6	5
198	MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management. <i>European Journal of Endocrinology</i> , 2021 , 185, R103-R111	6.5	3
197	Middle ear neuroendocrine tumours: Insight into their pathogenesis, diagnosis and management. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e13031	3.8	0
196	Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline. <i>The Lancet Child and Adolescent Health</i> , 2021 , 5, 662-676	14.5	6
195	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 654-656	18.1	13
194	GH deficiency in cancer survivors in the transition age: diagnosis and therapy. <i>Pituitary</i> , 2020 , 23, 432-456	4.3	2
193	The tumour microenvironment of pituitary neuroendocrine tumours. <i>Frontiers in Neuroendocrinology</i> , 2020 , 58, 100852	8.9	13
192	Thyroid disease in the time of COVID-19. <i>Endocrine</i> , 2020 , 68, 471-474	4	45
191	Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 278-291	18.1	27
190	Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	21

189	ENDOCRINOLOGY IN THE TIME OF COVID-19: Clinical management of neuroendocrine neoplasms (NENs). <i>European Journal of Endocrinology</i> , 2020 , 183, G79-G88	6.5	9
188	Neoplastic metastases to the endocrine glands. <i>Endocrine-Related Cancer</i> , 2020 , 27, R1-R20	5.7	17
187	The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs). <i>Endocrine-Related Cancer</i> , 2020 , 27, R375-R390	5.7	14
186	Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection. <i>Endocrine Connections</i> , 2020 , 9, X1-X2	3.5	
185	Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in pheochromocytomas and paragangliomas. <i>European Journal of Endocrinology</i> , 2020 , 183, 129-139	6.5	5
184	Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Trends in Endocrinology and Metabolism</i> , 2020 , 31, 239-255	8.8	5
183	Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. <i>Pituitary</i> , 2020 , 23, 322-325	4.3	21
182	The role of the tumour microenvironment in the angiogenesis of pituitary tumours. <i>Endocrine</i> , 2020 , 70, 593-606	4	5
181	Pheochromocytoma: An approach to diagnosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020 , 34, 101346	6.5	19
180	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019 , 160, 2600-2617	4.8	12
179	Nonneuroendocrine Neoplasms of the Pituitary Region. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3108-3123	5.6	8
178	Colonic Cancer and Acromegaly. <i>Frontiers in Endocrinology</i> , 2019 , 10, 390	5.7	15
177	Clinical and Pathological Aspects of Silent Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2473-2489	5.6	69
176	Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Pheochromocytoma and Paraganglioma. <i>Neuroendocrinology</i> , 2019 , 109, 287-298	5.6	35
175	Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. <i>Oncogene</i> , 2019 , 38, 5381-5395	9.2	39
174	The Medical Therapy of Craniopharyngiomas: The Way Ahead. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5751-5764	5.6	15
173	⁶⁸ Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5843-5852	5.6	20
172	What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?. <i>Clinical Endocrinology</i> , 2019 , 91, 708-715	3.4	8

171	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019 , 11,	6.6	65
170	Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenectomy for Non-ACTH-Secreting Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5316-5324	5.6	7
169	Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 172	7.3	35
168	Difference in survival between right- versus left-sided colorectal neuroendocrine neoplasms. <i>Journal of Zhejiang University: Science B</i> , 2019 , 20, 933-939	4.5	2
167	Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection. <i>Endocrine Connections</i> , 2019 , 8, 1082-1088	3.5	9
166	Plurihormonal Pit-1 lineage adenoma presenting as meningitis with recurrence after somatostatin analogue. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2019 , 2019,	1.4	1
165	ENDOCRINOLOGY AND ADOLESCENCE: Dealing with transition in young patients with pituitary disorders. <i>European Journal of Endocrinology</i> , 2019 , 181, R155-R171	6.5	12
164	Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. <i>Endocrine-Related Cancer</i> , 2019 , 26, 853-865	5.7	22
163	SAT-462 AIP Mutation-Positive Patients with Somatotropinomas End up Taller and Requiring Radiotherapy More Often Compared to AIP Mutation-Negative Patients: Data from 784 Familial and Young-Onset Cases. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
162	Etomidate in the management of severe Cushing's disease and MRSA bacteraemia in a district general hospital in the United Kingdom. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2019 , 2019,	1.4	1
161	The sinister side of Cushing's therapy. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 822-823	18.1	
160	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019 , 108, 54-62	5.6	41
159	Association of prolactin receptor (PRLR) variants with prolactinomas. <i>Human Molecular Genetics</i> , 2019 , 28, 1023-1037	5.6	12
158	Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy. <i>Neuroendocrinology</i> , 2019 , 108, 256-264	5.6	43
157	Metastatic Pheochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019 , 127, 117-128	2.3	25
156	Clinical, Endocrine and Imaging Characteristics of Patients with Primary Hypophysitis. <i>Hormone and Metabolic Research</i> , 2018 , 50, 296-302	3.1	22
155	Falsely elevated plasma metanephrine in patients taking midodrine. <i>Annals of Clinical Biochemistry</i> , 2018 , 55, 509-515	2.2	10
154	A prospective longitudinal study of Pasireotide in Nelson's syndrome. <i>Pituitary</i> , 2018 , 21, 247-255	4.3	17

153	Transsphenoidal surgery for pituitary tumours: frequency and predictors of delayed hyponatraemia and their relationship to early readmission. <i>European Journal of Endocrinology</i> , 2018 , 178, 247-253	6.5	24
152	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 404-415	18.1	43
151	Primary Ovarian Carcinoid: Extensive Clinical Experience With an Underrecognized Uncommon Entity. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 466-471	3.5	9
150	Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. <i>Endocrine</i> , 2018 , 59, 175-182	4	23
149	Is the new treatment for Cushing's disease too sweet?. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 2-3	18.1	1
148	The Short Synacthen (Corticotropin) Test Can Be Used to Predict Recovery of Hypothalamo-Pituitary-Adrenal Axis Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3050-3059	5.6	26
147	Aggressive and malignant pituitary tumours: state-of-the-art. <i>Endocrine-Related Cancer</i> , 2018 , 25, R559-R575	5.7	25
146	Liver biochemical abnormalities in Turner syndrome: A comprehensive characterization of an adult population. <i>Clinical Endocrinology</i> , 2018 , 89, 667-676	3.4	8
145	The Ectopic Adrenocorticotrophic Hormone Syndrome: Rarely Easy, Always Challenging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 409-425	5.5	28
144	Circadian Rhythm of Glucocorticoid Administration Entrain Clock Genes in Immune Cells: A DREAM Trial Ancillary Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2998-3009	5.6	35
143	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. <i>Neuroendocrinology</i> , 2017 , 105, 196-200	5.6	108
142	Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017 , 125, 365-367	2.3	6
141	Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. <i>Targeted Oncology</i> , 2017 , 12, 235-241	5	31
140	Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. <i>Endocrine-Related Cancer</i> , 2017 , 24, R239-R259	5.7	11
139	Pachydermoperiostosis Masquerading as Acromegaly. <i>Journal of the Endocrine Society</i> , 2017 , 1, 109-112	0.4	7
138	Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1889-1897	5.6	45
137	Paraneoplastic endocrine syndromes. <i>Endocrine-Related Cancer</i> , 2017 , 24, R173-R190	5.7	34
136	Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy. <i>Neuroendocrinology</i> , 2017 , 105, 105-114	5.6	23

135	Pasireotide and octreotide in the treatment of severe late dumping syndrome. <i>Clinical Case Reports (discontinued)</i> , 2017 , 5, 1608-1611	0.7	4
134	The clinical genetics of pheochromocytoma and paraganglioma. <i>Archives of Endocrinology and Metabolism</i> , 2017 , 61, 490-500	2.2	15
133	Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour. <i>Acta Medica Portuguesa</i> , 2017 , 30, 421-425	1.4	5
132	Pheochromocytoma and Paraganglioma. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 956, 239-259	3.6	36
131	Chemotherapy in NETs: When and how. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 485-497	10.5	16
130	Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. <i>Clinical Endocrinology</i> , 2017 , 86, 177-184	3.4	29
129	The selective PI3K inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. <i>PLoS ONE</i> , 2017 , 12, e0182852	3.7	17
128	MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts. <i>European Journal of Endocrinology</i> , 2017 , 177, R219-R229	6.5	8
127	Treating prolactinomas with dopamine agonists: always worth the gamble?. <i>Endocrine</i> , 2016 , 51, 205-10	4	34
126	Cushing's Syndrome		2
125	Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. <i>Endocrine</i> , 2016 , 54, 778-787	4	10
124	Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. <i>Acta Neuropathologica Communications</i> , 2016 , 4, 56	7.3	77
123	Pituitary stalk thickening: the role of an innovative MRI imaging analysis which may assist in determining clinical management. <i>European Journal of Endocrinology</i> , 2016 , 175, 255-63	6.5	22
122	Do patients with incidentally discovered bilateral adrenal nodules represent an early form of ARMC5-mediated bilateral macronodular hyperplasia?. <i>Endocrine</i> , 2016 , 53, 801-8	4	9
121	Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. <i>Endocrinology</i> , 2016 , 157, 1789-98	4.8	22
120	Quality indicators in pituitary surgery: a need for reliable and valid assessments. What should be measured?. <i>Clinical Endocrinology</i> , 2016 , 84, 485-8	3.4	6
119	Current strategies for the treatment of severe Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2016 , 11, 65-79	4.1	
118	Appendiceal neuroendocrine neoplasms: diagnosis and management. <i>Endocrine-Related Cancer</i> , 2016 , 23, R27-41	5.7	34

117	Chordoid glioma of the third ventricle: a patient presenting with SIADH and a review of this rare tumor. <i>Pituitary</i> , 2016 , 19, 356-61	4.3	11
116	Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome. <i>Drugs</i> , 2016 , 76, 447-58	12.1	22
115	Somatic and germline mutations in NETs: Implications for their diagnosis and management. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016 , 30, 115-27	6.5	9
114	Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. <i>European Journal of Endocrinology</i> , 2016 , 174, 137-45	6.5	40
113	A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016 , 2016,	1.4	7
112	Health-related quality of life in patients treated for nonfunctioning pituitary adenomas during the years 2000-2010. <i>Clinical Endocrinology</i> , 2016 , 84, 532-9	3.4	15
111	Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2364-2374	15.1	86
110	Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E531-41	5.6	127
109	60 YEARS OF NEUROENDOCRINOLOGY: Celebrating 60 years of neuroendocrinology. <i>Journal of Endocrinology</i> , 2015 , 226, E1	4.7	1
108	Evaluation of genotype-phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome. <i>European Journal of Endocrinology</i> , 2015 , 172, 217-26	6.5	10
107	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E1242-54	5.6	115
106	Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. <i>European Journal of Endocrinology</i> , 2015 , 173, 633-42	6.5	81
105	Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. <i>European Journal of Endocrinology</i> , 2015 , 173, R101-13	6.5	57
104	Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4146-54	5.6	125
103	The diagnosis and management of inpatient hyponatraemia and SIADH. <i>European Journal of Clinical Investigation</i> , 2015 , 45, 888-94	4.6	54
102	The expanding role of somatostatin analogues in the treatment of neuroendocrine tumours: the CLARINET study. <i>Clinical Endocrinology</i> , 2015 , 83, 759-61	3.4	8
101	Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. <i>PLoS ONE</i> , 2015 , 10, e0143830	3.7	11
100	The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015 , 16, 481-7	3	2

99	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015 , 26, 1604-20	10.3	363
98	Transient diabetes insipidus in pregnancy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015 , 2015, 150078	1.4	11
97	Cushing's Disease - Quality of Life, Recurrence and Long-term Morbidity. <i>European Endocrinology</i> , 2015 , 11, 34-38	3.4	2
96	A patient with an apparently sporadic pheochromocytoma with a rearranged during transfection codon 635 variant: a mild form of multiple endocrine neoplasia type 2?. <i>Endocrine Practice</i> , 2014 , 20, e65-8	3.2	2
95	BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. <i>Acta Neuropathologica</i> , 2014 , 127, 927-9	14.3	87
94	The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas. <i>Endocrine</i> , 2014 , 46, 387-96	4	15
93	ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1784-92	5.6	73
92	Adrenal insufficiency in acute oral opiate therapy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2014 , 2014, 130071	1.4	11
91	Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. <i>European Journal of Endocrinology</i> , 2014 , 171, K1-5	6.5	38
90	Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. <i>Endocrinology</i> , 2014 , 155, 2377-90	4.8	14
89	Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. <i>European Journal of Endocrinology</i> , 2014 , 171, 659-66	6.5	34
88	Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. <i>European Journal of Endocrinology</i> , 2014 , 171, 705-10	6.5	11
87	Recurrent pancreatitis in a patient with familial hypocalciuric hypercalcaemia treated successfully with cinacalcet. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2014 , 2014, 140050	1.4	8
86	Cushing's Syndrome 2014 , 99-111		3
85	The nuclear option for insulinomas. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 82-4	18.1	2
84	Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. <i>Endocrinology</i> , 2013 , 154, 646-55	4.8	38
83	Dandy-Walker malformation, papillary thyroid carcinoma, and SDHD-associated paraganglioma syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4595-6	5.6	4
82	Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. <i>European Journal of Endocrinology</i> , 2013 , 169, R165-75	6.5	81

81	The management of head-and-neck paragangliomas. <i>Endocrine-Related Cancer</i> , 2013 , 20, R291-305	5.7	53
80	Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. <i>European Journal of Endocrinology</i> , 2013 , 168, 639-48	6.5	121
79	Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. <i>Chest</i> , 2013 , 143, 955-962	5.3	95
78	Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. <i>European Journal of Endocrinology</i> , 2012 , 167, 137-43	6.5	115
77	Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1411-20	5.6	104
76	GnRH analogue use in postmenopausal hyperandrogenism: long-term remission. <i>Endocrine</i> , 2012 , 41, 342-3	4	
75	Mini-review: pheochromocytomas causing the ectopic ACTH syndrome. <i>Endocrine</i> , 2012 , 42, 69-73	4	31
74	Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. <i>Endocrine Pathology</i> , 2012 , 23, 21-33	4.2	47
73	Rathke's cleft cysts. <i>Clinical Endocrinology</i> , 2012 , 76, 151-60	3.4	96
72	Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. <i>European Journal of Endocrinology</i> , 2012 , 167, 1-5	6.5	95
71	Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?. <i>European Journal of Endocrinology</i> , 2012 , 166, 21-6	6.5	41
70	Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. <i>Journal of Molecular Endocrinology</i> , 2012 , 49, 79-96	4.5	41
69	The road less travelled. <i>Endocrine-Related Cancer</i> , 2012 , 19, P13-6	5.7	
68	Practical aspects of etomidate use in the management of hypercortisolaemia. <i>European Journal of Endocrinology</i> , 2012 , 167, 729	6.5	27
67	Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 1133-48	4.6	119
66	Pheochromocytomas and paragangliomas: assessment of malignant potential. <i>Endocrine</i> , 2011 , 40, 354-65	4.5	49
65	AIP mutation in pituitary adenomas in the 18th century and today. <i>New England Journal of Medicine</i> , 2011 , 364, 43-50	59.2	122
64	Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. <i>Clinical Endocrinology</i> , 2010 , 72, 305-11	3.4	26

63	90Y-edotreotide for metastatic carcinoid refractory to octreotide. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1652-9	2.2	256
62	Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. <i>European Journal of Endocrinology</i> , 2010 , 162, 971-8	6.5	50
61	Novel insights in the diagnosis of Cushing's syndrome. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 35-43	5.6	23
60	The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. <i>Molecular and Cellular Endocrinology</i> , 2010 , 315, 87-94	4.4	31
59	Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). <i>Trends in Endocrinology and Metabolism</i> , 2010 , 21, 419-27	8.8	82
58	Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2611-9	27.4	144
57	Clinical Review#: The diagnosis and management of central hypoadrenalism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 4855-63	5.6	125
56	The ectopic ACTH syndrome. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010 , 11, 117-26	10.5	140
55	Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. <i>Human Mutation</i> , 2010 , 31, 950-60	4.7	136
54	Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. <i>Endocrine-Related Cancer</i> , 2009 , 16, 515-25	5.7	29
53	Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. <i>Endocrine-Related Cancer</i> , 2009 , 16, 45-58	5.7	77
52	The molecular biology of pituitary tumors: a personal perspective. <i>Pituitary</i> , 2009 , 12, 265-70	4.3	19
51	Response to MIBG scans for phaeochromocytoma: time to abandon the technique?. <i>Clinical Endocrinology</i> , 2009 , 70, 968-969	3.4	
50	Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 709-28	5.6	701
49	Diagnosis of insulinoma in a patient with hypoglycemia without obvious hyperinsulinemia. <i>Nature Reviews Endocrinology</i> , 2009 , 5, 628-31	15.2	9
48	123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal pheochromocytomas: CT and MRI correlation. <i>Clinical Endocrinology</i> , 2008 , 69, 181-8	3.4	105
47	Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. <i>Neuroendocrinology</i> , 2008 , 87, 168-81	5.6	103
46	The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2390-401	5.6	242

45	The diagnosis and management of parasellar tumours of the pituitary. <i>Endocrine-Related Cancer</i> , 2008 , 15, 885-903	5.7	39
44	Medical Therapy for Cushing's Disease [Past and Future Modes of Treatment. <i>European Endocrinology</i> , 2008 , 4, 74	3.4	5
43	Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1729-35	5.6	46
42	The diagnosis and management of malignant pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2007 , 14, 569-85	5.7	236
41	Endocrine manifestations in Langerhans cell histiocytosis. <i>Trends in Endocrinology and Metabolism</i> , 2007 , 18, 252-7	8.8	82
40	The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 371-7	5.6	355
39	Cushing's syndrome caused by an occult source: difficulties in diagnosis and management. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 642-7		29
38	Cushing's syndrome. <i>Lancet, The</i> , 2006 , 367, 1605-17	4.0	967
37	Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1073, 332-47	6.5	90
36	Clinical review: Diagnosis and management of pituitary carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3089-99	5.6	258
35	Commentary: imaging of islet-cell tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2005 , 19, 241-3	6.5	3
34	A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. <i>PLoS Genetics</i> , 2005 , 1, 72-80	6	335
33	Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4963-9	5.6	93
32	Akting and cycling: a tale of the pituitary. <i>Hormone Research in Paediatrics</i> , 2004 , 62 Suppl 3, 117-23	3.3	4
31	Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5299-306	5.6	116
30	Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and pheochromocytoma susceptibility. <i>Clinical Endocrinology</i> , 2003 , 59, 728-33	3.4	81
29	Cell Cycle Dysregulation in Human Pituitary Tumours. <i>Clinical Science</i> , 2002 , 103, 22P-22P		
28	The release of leptin and its effect on hormone release from human pituitary adenomas. <i>Clinical Endocrinology</i> , 2001 , 54, 781-9	3.4	27

27	The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2001 , 55, 575-87	3.4	32
26	Leptin in pituitary adenomas--a novel paracrine regulatory system. <i>Pituitary</i> , 2001 , 4, 49-55	4.3	8
25	Presence of ghrelin in normal and adenomatous human pituitary. <i>Endocrine</i> , 2001 , 14, 101-4		94
24	The roles of carbon monoxide and nitric oxide in the control of the neuroendocrine stress response: complementary or redundant. <i>Stress</i> , 2001 , 4, 3-11	3	
23	Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. <i>Clinical Endocrinology</i> , 2000 , 53, 453-9	3.4	44
22	The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2489-95	5.6	86
21	Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2238-40	5.6	57
20	Hexarelin as a test of pituitary reserve in patients with pituitary disease. <i>Clinical Endocrinology</i> , 1999 , 51, 369-75	3.4	14
19	Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. <i>Oncogene</i> , 1998 , 16, 69-76	9.2	107
18	The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. <i>Endocrine Reviews</i> , 1998 , 19, 647-72	27.2	493
17	The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. <i>British Journal of Pharmacology</i> , 1997 , 120, 781-4	8.6	66
16	Thyroid peroxidase: evidence for disease gene exclusion in Pendred's syndrome. <i>Clinical Endocrinology</i> , 1996 , 44, 441-6	3.4	8
15	Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. <i>Clinical Endocrinology</i> , 1996 , 45, 699-706	3.4	43
14	Serum cortisol is not an accurate predictor of the integrity of the hypothalamic-pituitary-adrenocortical axis. <i>Clinical Endocrinology</i> , 1995 , 42, 101-2	3.4	5
13	A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1995 , 43, 545-50	3.4	184
12	Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone. <i>Clinical Endocrinology</i> , 1995 , 43, 583-9	3.4	18
11	Interleukin-1 beta and interleukin-6 stimulate neurohypophysial hormone release in vitro. <i>Journal of Neuroendocrinology</i> , 1994 , 6, 179-84	3.8	73
10	New uses for an old peptide: desmopressin and Cushing's syndrome. <i>Clinical Endocrinology</i> , 1993 , 38, 461-2	3.4	8

9	Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992 , 241, 317-22	5.1	47
8	What is the cause of Cushing's disease?. <i>Clinical Endocrinology</i> , 1992 , 36, 451-2	3.4	9
7	The diagnosis and differential diagnosis of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1991 , 34, 317-30	3.4	118
6	Enhancement of the sympathoadrenal response to the cold-pressor test by naloxone in man. <i>Clinical Science</i> , 1985 , 69, 365-8	6.5	28
5	Secretion of ACTH, LPH and beta-endorphin from human pituitary tumours in vitro. <i>Clinical Endocrinology</i> , 1980 , 13, 197-205	3.4	40
4	Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. <i>British Journal of Pharmacology</i> , 1980 , 71, 569-73	8.6	25
3	Desmopressin Normalizes the Blunted Adrenocorticotropin Response to Corticotropin-Releasing Hormone in Melancholic Depression: Evidence of Enhanced Vasopressinergic Responsivity		21
2	The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin		33
1	Distinguishing Cushing's Disease from the Ectopic ACTH Syndrome -Needles in a Haystack or Hiding in Plain Sight?. <i>Journal of Neuroendocrinology</i> ,	3.8	15